Cargando…

Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial

PURPOSE: The purpose of the present study was to investigate the efficacy and safety of remimazolam besylate compared with dexmedetomidine for the relief of agitated delirium in non-intubated older patients after orthopedic surgery. PATIENTS AND METHODS: Seventy-five patients were randomly divided i...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Yang, Qin, Zhijun, Wu, Qianyun, Liu, Linsong, Yang, Xi, Ju, Xuan, Zhang, Ying, Liu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354763/
https://www.ncbi.nlm.nih.gov/pubmed/35937566
http://dx.doi.org/10.2147/DDDT.S373772
_version_ 1784763142746669056
author Deng, Yang
Qin, Zhijun
Wu, Qianyun
Liu, Linsong
Yang, Xi
Ju, Xuan
Zhang, Ying
Liu, Lei
author_facet Deng, Yang
Qin, Zhijun
Wu, Qianyun
Liu, Linsong
Yang, Xi
Ju, Xuan
Zhang, Ying
Liu, Lei
author_sort Deng, Yang
collection PubMed
description PURPOSE: The purpose of the present study was to investigate the efficacy and safety of remimazolam besylate compared with dexmedetomidine for the relief of agitated delirium in non-intubated older patients after orthopedic surgery. PATIENTS AND METHODS: Seventy-five patients were randomly divided into two groups. Patients assigned to the remimazolam group received a loading dose of 0.075 mg/kg remimazolam besylate over 1 minute, followed by a continuous infusion of 0.1 to 0.3 mg/kg/h. Subjects randomized to the dexmedetomidine group received a loading infusion of 0.5 μg/kg dexmedetomidine over 10 minutes, followed by a maintenance dose of 0.2 to 0.7 μg/kg/h. Meanwhile, RASS score-guided dose titration was followed. To assess the efficacy of the study drugs in terms of time to resolution of agitation, time to first achievement of target sedation, percentage of time within the target sedation range, and time to delirium resolution. Safety of the sedatives was evaluated by adverse events during hospitalization. RESULTS: Time to resolution of agitation did not differ between the two groups. The time to first achievement of target sedation was 19.0 (9.5 to 31.0) minutes for remimazolam besylate vs 43.5 (15.0 to 142.5) minutes for dexmedetomidine (P < 0.001). Percentage of time within the target sedation range was 77.8% for remimazolam besylate-treated patients and 67.4% for dexmedetomidine-treated patients (P = 0.001). Patients in the remimazolam group had longer time to delirium resolution (29.5 [21.3 to 32.5] hours) than those in the dexmedetomidine group (22.8 [18.9 to 28.5] hours) (P = 0.042). Patients sedated with remimazolam besylate had more oversedation (P = 0.036) but less hypotension (P = 0.007). CONCLUSION: Compared with dexmedetomidine, remimazolam besylate was equally effective in relieving agitation, and resulted in earlier achievement of sedation goal and more controllable sedation. Remimazolam may be an ideal agent for obtaining rapid tranquillisation.
format Online
Article
Text
id pubmed-9354763
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-93547632022-08-06 Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial Deng, Yang Qin, Zhijun Wu, Qianyun Liu, Linsong Yang, Xi Ju, Xuan Zhang, Ying Liu, Lei Drug Des Devel Ther Original Research PURPOSE: The purpose of the present study was to investigate the efficacy and safety of remimazolam besylate compared with dexmedetomidine for the relief of agitated delirium in non-intubated older patients after orthopedic surgery. PATIENTS AND METHODS: Seventy-five patients were randomly divided into two groups. Patients assigned to the remimazolam group received a loading dose of 0.075 mg/kg remimazolam besylate over 1 minute, followed by a continuous infusion of 0.1 to 0.3 mg/kg/h. Subjects randomized to the dexmedetomidine group received a loading infusion of 0.5 μg/kg dexmedetomidine over 10 minutes, followed by a maintenance dose of 0.2 to 0.7 μg/kg/h. Meanwhile, RASS score-guided dose titration was followed. To assess the efficacy of the study drugs in terms of time to resolution of agitation, time to first achievement of target sedation, percentage of time within the target sedation range, and time to delirium resolution. Safety of the sedatives was evaluated by adverse events during hospitalization. RESULTS: Time to resolution of agitation did not differ between the two groups. The time to first achievement of target sedation was 19.0 (9.5 to 31.0) minutes for remimazolam besylate vs 43.5 (15.0 to 142.5) minutes for dexmedetomidine (P < 0.001). Percentage of time within the target sedation range was 77.8% for remimazolam besylate-treated patients and 67.4% for dexmedetomidine-treated patients (P = 0.001). Patients in the remimazolam group had longer time to delirium resolution (29.5 [21.3 to 32.5] hours) than those in the dexmedetomidine group (22.8 [18.9 to 28.5] hours) (P = 0.042). Patients sedated with remimazolam besylate had more oversedation (P = 0.036) but less hypotension (P = 0.007). CONCLUSION: Compared with dexmedetomidine, remimazolam besylate was equally effective in relieving agitation, and resulted in earlier achievement of sedation goal and more controllable sedation. Remimazolam may be an ideal agent for obtaining rapid tranquillisation. Dove 2022-08-01 /pmc/articles/PMC9354763/ /pubmed/35937566 http://dx.doi.org/10.2147/DDDT.S373772 Text en © 2022 Deng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Deng, Yang
Qin, Zhijun
Wu, Qianyun
Liu, Linsong
Yang, Xi
Ju, Xuan
Zhang, Ying
Liu, Lei
Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial
title Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial
title_full Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial
title_fullStr Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial
title_full_unstemmed Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial
title_short Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial
title_sort efficacy and safety of remimazolam besylate versus dexmedetomidine for sedation in non-intubated older patients with agitated delirium after orthopedic surgery: a randomized controlled trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354763/
https://www.ncbi.nlm.nih.gov/pubmed/35937566
http://dx.doi.org/10.2147/DDDT.S373772
work_keys_str_mv AT dengyang efficacyandsafetyofremimazolambesylateversusdexmedetomidineforsedationinnonintubatedolderpatientswithagitateddeliriumafterorthopedicsurgeryarandomizedcontrolledtrial
AT qinzhijun efficacyandsafetyofremimazolambesylateversusdexmedetomidineforsedationinnonintubatedolderpatientswithagitateddeliriumafterorthopedicsurgeryarandomizedcontrolledtrial
AT wuqianyun efficacyandsafetyofremimazolambesylateversusdexmedetomidineforsedationinnonintubatedolderpatientswithagitateddeliriumafterorthopedicsurgeryarandomizedcontrolledtrial
AT liulinsong efficacyandsafetyofremimazolambesylateversusdexmedetomidineforsedationinnonintubatedolderpatientswithagitateddeliriumafterorthopedicsurgeryarandomizedcontrolledtrial
AT yangxi efficacyandsafetyofremimazolambesylateversusdexmedetomidineforsedationinnonintubatedolderpatientswithagitateddeliriumafterorthopedicsurgeryarandomizedcontrolledtrial
AT juxuan efficacyandsafetyofremimazolambesylateversusdexmedetomidineforsedationinnonintubatedolderpatientswithagitateddeliriumafterorthopedicsurgeryarandomizedcontrolledtrial
AT zhangying efficacyandsafetyofremimazolambesylateversusdexmedetomidineforsedationinnonintubatedolderpatientswithagitateddeliriumafterorthopedicsurgeryarandomizedcontrolledtrial
AT liulei efficacyandsafetyofremimazolambesylateversusdexmedetomidineforsedationinnonintubatedolderpatientswithagitateddeliriumafterorthopedicsurgeryarandomizedcontrolledtrial